XML 42 R30.htm IDEA: XBRL DOCUMENT
v2.4.0.8

Summary of Revenue Recognized under Agreement with GSK (Detail) (USD $) In Thousands, unless otherwise specified | 1 Months Ended | 3 Months Ended | 9 Months Ended | 12 Months Ended
--- | --- | --- | --- | ---
Dec. 31, 2008 | Sep. 30, 2013 | Sep. 30, 2012 | Sep. 30, 2013 | Sep. 30, 2012 | Dec. 31, 2011
Product Information [Line Items] |  |  |  |  |  |
Total |  | $ 2,927 | $ 2,874 | $ 8,404 | $ 7,908 |
Grant revenue |  | 1,700 | 1,219 | 3,855 | 3,188 |
National Institutes of Health |  |  |  |  |  |
Product Information [Line Items] |  |  |  |  |  |
Grant revenue |  | 235 | 119 | 730 | 348 |
Glaxo, Smith, Kline |  |  |  |  |  |
Product Information [Line Items] |  |  |  |  |  |
Initial payment | 10,000 | 357 | 357 | 1,071 | 1,071 |
Performance of research activities |  |  |  |  |  | 12,000
Astra Zeneca |  |  |  |  |  |
Product Information [Line Items] |  |  |  |  |  |
Initial payment |  | 180 | 180 | 540 | 540 |
Performance of research activities |  | 573 | 513 | 1,738 | 1,991 |
Total |  | 753 | 693 | 2,278 | 2,531 |
National Institute Of Allergy And Infectious Diseases |  |  |  |  |  |
Product Information [Line Items] |  |  |  |  |  |
Grant revenue |  | $ 1,465 | $ 1,100 | $ 3,125 | $ 2,840 |

X
- Definition Revenue from collaboration agreement. + References No definition available. + Details
Name: | dvax_CollaborationRevenue
Namespace Prefix: | dvax_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | us-gaap_ProductInformationLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Revenue earned during the period from non-repayable sum of money awarded to an entity to carry out a specific purpose as provided in grant agreements. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.1(e)) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688 + Details
Name: | us-gaap_RevenueFromGrants
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The amount of consideration recognized during the period for the milestone or milestones. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 28 -Section 50 -Paragraph 2 -Subparagraph (e) -URI http://asc.fasb.org/extlink&oid=19771982&loc=SL6892177-166501 + Details
Name: | us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.1) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 1 -Article 5 + Details
Name: | us-gaap_Revenues
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration